Trium Capital LLP F Star Therapeutics, Inc. Transaction History

Trium Capital LLP

  • $350 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 31, 2023
BUY
$4.09 - $6.86 $2.78 Million - $4.66 Million
679,744 New
679,744 $4.3 Million

Others Institutions Holding FSTX

# of Institutions
3
Shares Held
44.7K
Call Options Held
0
Put Options Held
0
View Full List

About F-star Therapeutics, Inc.

FSTX Quotes by TradingView
  • Ticker FSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,584,700
  • Description
  • F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...
More about FSTX
Track This Portfolio

Track Trium Capital LLP Portfolio

Follow Trium Capital LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trium Capital LLP, based on Form 13F filings with the SEC.

News

Stay updated on Trium Capital LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email